{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:06:20Z","timestamp":1787022380147,"version":"build-2736575974"},"reference-count":49,"publisher":"Houston Methodist DeBakey Heart & Vascular Center","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,24]]},"DOI":"10.14797\/mdcvj.887","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T07:54:38Z","timestamp":1632470078000},"page":"28-35","source":"Crossref","is-referenced-by-count":16,"title":["Past, Present, and Future of Familial Hypercholesterolemia Management"],"prefix":"10.14797","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4157-664X","authenticated-orcid":false,"given":"Viviane Z.","family":"Rocha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-6582","authenticated-orcid":false,"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5826","reference":[{"key":"key20210924072707_B1","doi-asserted-by":"crossref","first-page":"17093","DOI":"10.1038\/nrdp.2017.93","article-title":"Familial hypercholesterolaemia","volume":"3","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"key20210924072707_B2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.pcad.2019.10.003","article-title":"Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management","volume":"62","year":"2019","journal-title":"Prog Cardiovasc Dis"},{"key":"key20210924072707_B3","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","year":"2008","journal-title":"BMJ"},{"issue":"22","key":"key20210924072707_B4","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis","volume":"141","year":"2020","journal-title":"Circulation"},{"issue":"20","key":"key20210924072707_B5","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects","volume":"75","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"key20210924072707_B6","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/CIRCULATIONAHA.120.046961","article-title":"What Is Familial Hypercholesterolemia, and Why Does It Matter?","volume":"141","year":"2020","journal-title":"Circulation"},{"issue":"22","key":"key20210924072707_B7","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia","volume":"67","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9874","key":"key20210924072707_B8","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","article-title":"Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study","volume":"381","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"key20210924072707_B9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-Term Evolocumab in Patients With Familial Hypercholesterolemia","volume":"75","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"key20210924072707_B10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"key20210924072707_B11","article-title":"Atherosclerosis","volume":"5","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"32","key":"key20210924072707_B12","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"key20210924072707_B13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia","volume":"16","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"key20210924072707_B14","first-page":"332","article-title":"The association between hypercholesterolemia and sitosterolemia, and report of a sitosterolemia kindred","volume":"24","year":"2013","journal-title":"J Clin Lipidol"},{"issue":"4","key":"key20210924072707_B15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MOL.0b013e328361f6c6","article-title":"Lysosomal acid lipase A and the hypercholesterolaemic phenotype","volume":"24","year":"2013","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"key20210924072707_B16","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jacl.2020.07.010","article-title":"Failure of cosegregation between a rare STAP1 missense variant and hypercholesterolemia","volume":"14","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"4","key":"key20210924072707_B17","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1161\/ATVBAHA.119.313470","article-title":"Taking One Step Back in Familial Hypercholesterolemia: STAP1 Does Not Alter Plasma LDL (Low-Density Lipoprotein) Cholesterol in Mice and Humans","volume":"40","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"key20210924072707_B18","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jacc.2019.05.043","article-title":"Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia","volume":"74","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"key20210924072707_B19","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association","volume":"132","year":"2015","journal-title":"Circulation"},{"issue":"12","key":"key20210924072707_B20","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1161\/ATVBAHA.116.308027","article-title":"Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically","volume":"36","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"key20210924072707_B21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel","volume":"72","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20210924072707_B22","article-title":"Understanding Implementation Challenges to Genetic Testing for Familial Hypercholesterolemia in the United States","volume":"9","year":"2019","journal-title":"J Pers Med"},{"issue":"1","key":"key20210924072707_B23","first-page":"lsz016","article-title":"Genetic discrimination: emerging ethical challenges in the context of advancing technology","volume":"7","year":"2019","journal-title":"J Law Biosci"},{"issue":"11","key":"key20210924072707_B24","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jacc.2015.07.017","article-title":"Universal Screening for Familial Hypercholesterolemia in Children","volume":"66","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"key20210924072707_B25","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1602777","article-title":"Child-Parent Familial Hypercholesterolemia Screening in Primary Care","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"key20210924072707_B26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2018.04.040","article-title":"Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register","volume":"274","year":"2018","journal-title":"Atherosclerosis"},{"issue":"2","key":"key20210924072707_B27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/2047487316676135","article-title":"Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992\u20132013","volume":"24","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"key20210924072707_B28","first-page":"2508","article-title":"Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica","volume":"40","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"key20210924072707_B29","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol","volume":"39","year":"2018","journal-title":"Eur Heart J"},{"issue":"22","key":"key20210924072707_B30","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study)","volume":"135","year":"2017","journal-title":"Circulation"},{"issue":"9","key":"key20210924072707_B31","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.jcmg.2018.09.019","article-title":"Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy","volume":"12","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"key20210924072707_B32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2016.05.023","article-title":"Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia","volume":"250","year":"2016","journal-title":"Atherosclerosis"},{"key":"key20210924072707_B33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2020.12.012","article-title":"Familial hypercholesterolemia and cardiovascular disease in older individuals","volume":"318","year":"2021","journal-title":"Atherosclerosis"},{"issue":"7","key":"key20210924072707_B34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study","volume":"4","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"key20210924072707_B35","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jacl.2017.07.008","article-title":"Cardiovascular disease in familial hypercholesterolemia: Validation and refinement of the Montreal-FH-SCORE","volume":"11","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"24","key":"key20210924072707_B36","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"key20210924072707_B37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2020.06.011","article-title":"SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia","volume":"306","year":"2020","journal-title":"Atherosclerosis"},{"key":"key20210924072707_B38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2018.11.014","article-title":"Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register","volume":"281","year":"2019","journal-title":"Atherosclerosis"},{"key":"key20210924072707_B39","article-title":"The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"key20210924072707_B40","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jcmg.2019.11.001","article-title":"Absence of Coronary Artery Calcification in Middle-Aged Familial Hypercholesterolemia Patients Without Atherosclerotic Cardiovascular Disease","volume":"13","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"key20210924072707_B41","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up","volume":"67","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key20210924072707_B42","article-title":"Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"15","key":"key20210924072707_B43","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1161\/CIRCULATIONAHA.120.049057","article-title":"Coronary Artery Calcification in Familial Hypercholesterolemia: An Opportunity for Risk Assessment and Shared Decision Making With the Power of Zero?","volume":"142","year":"2020","journal-title":"Circulation"},{"issue":"16","key":"key20210924072707_B44","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"key20210924072707_B45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11883-014-0465-6","article-title":"Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances","volume":"17","year":"2015","journal-title":"Curr Atheroscler Rep"},{"issue":"8","key":"key20210924072707_B46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for Homozygous Familial Hypercholesterolemia","volume":"383","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"key20210924072707_B47","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in Patients with Refractory Hypercholesterolemia","volume":"383","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"key20210924072707_B48","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jmedgenet-2018-105713","article-title":"Review of the scientific evolution of gene therapy for the treatment of homozygous familial hypercholesterolaemia: past, present and future perspectives","volume":"56","year":"2019","journal-title":"J Med Genet"},{"issue":"2","key":"key20210924072707_B49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamacardio.2019.5173","article-title":"Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action","volume":"5","year":"2020","journal-title":"JAMA Cardiol"}],"container-title":["Methodist DeBakey Cardiovascular Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T07:55:20Z","timestamp":1632470120000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.houstonmethodist.org\/articles\/10.14797\/mdcvj.887\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,9,24]]}},"alternative-id":["10.14797\/mdcvj.887"],"URL":"https:\/\/doi.org\/10.14797\/mdcvj.887","relation":{},"ISSN":["1947-6108"],"issn-type":[{"value":"1947-6108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}